You are here

Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Hospital Universitario A Coruna
A Coruna, , 15006 Spain
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
50-99 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Age ≥ 50 years

- Left ventricular hypertrophy (LVH): (Defined by end-diastolic LV maximum wall
thickness (MWT) ≥15mm in ECHO)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Etiological diagnosis explaining the LVH:

o Sarcomeric HCM, Myeloma, Fabry disease, Sarcoidosis, Any type of amyloidosis (AA,
AL, TTR*...)

- Severe aortic stenosis (Aortic valve area (AVA)

NCT03842163
Pfizer
Recruiting
Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now